Organisation paid for research Program year 2025 Source: CMS Open Payments

Affiliated Oncologists, LLC

Neither a doctor nor a teaching hospital

Research payments

$511,541

146 payments

Through program year 2025, Affiliated Oncologists, LLC is reported as receiving $511,541 in research payments, across 146 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$72,377	8
2024	Research	$107,759	6
2023	Research	$20,089	8
2022	Research	$104,999	13
2021	Research	$140,203	31
2020	Research	$66,114	80

Breakdown

Who paid Research payments · program years 2020–2025

Amgen Inc. $228,601 18 payments
Mirati Therapeutics, Inc. $104,216 4 payments
E.R. Squibb & Sons, L.L.C. $59,211 2 payments
Radius Health, Inc. $39,230 39 payments
Janssen Research & Development, LLC $30,946 67 payments
AstraZeneca Pharmaceuticals LP $26,437 7 payments
Seattle Genetics, Inc. $13,492 8 payments
Novartis Pharmaceuticals Corporation $9,409 1 payment

Studies the money was for Research payments · program years 2020–2025

SELECT-1st relapse after len-containing regimen $122,142 3 payments
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $94,916 2 payments
Select $83,007 3 payments
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% $59,211 2 payments
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer $24,863 65 payments
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community $15,217 3 payments
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment $13,492 8 payments
AMG 510_Ph3 NSCLC Monotherapy Comparator Trial $11,444 5 payments
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) $9,409 1 payment
Rad1901-308 $9,321 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.